P
Pharming Group N.V. (PHAR)
NGM – Real Time Price. Currency in USD
13.09
+0.47 (3.69%)
At close: May 12, 2026, 4:00 PM EDT
13.09
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
13.09
+0.47 (3.69%)
At close: May 12, 2026, 4:00 PM EDT
13.09
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kẟ inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Name | Position |
|---|---|
| Dr. Alexander Breidenbach M.B.A. | Chief Business Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Magnus Hansson | Medical Director |
| Mr. Fabrice Chouraqui Ph.D., Pharm.D. | CEO & Executive Director |
| Mr. Kenneth Lynard EMBA | Chief Financial Officer |
| Mr. Michael K. Levitan | VP of Investor Relations & Corporate Communications |
| Mr. Ruud Van Outersterp | Chief Legal & Compliance Officer |
| Ms. Ines Bernal | Chief People Officer |
| Ms. Leverne Marsh | Chief Commercial Officer |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 6-K | pharminggroupannouncespres.htm |
| 2026-04-16 | 6-K | pharminggroupannouncesthe2.htm |
| 2026-04-13 | 20-F/A | pharm-20251231.htm |
| 2026-04-02 | 6-K | pharminggroupannouncesthef.htm |
| 2026-04-02 | 20-F | pharm-20251231.htm |
| 2026-03-27 | 6-K | pharminggroupreceivesposit.htm |
| 2026-03-24 | 6-K | pharminggroupannouncesappr.htm |
| 2026-03-12 | 6-K | a2025q4pressrelease.htm |
| 2026-02-03 | 6-K | pharminggroupannounces2026.htm |
| 2026-02-02 | 6-K | pharminggroupreceivescompl.htm |